-
Mashup Score: 8
Disclosures. Shadman:Fate Therapeutics: Consultancy; Genmab: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Bristol Myers Squibb: Consul
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39Paper: Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy - 5 month(s) ago
Program: Oral and Poster Abstracts Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I 1 University of Washington, Seattle, WA 2 Fred Hutchinson Cancer Center, Seattle, WA 3 Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 4 Clinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of Washington, Seattle, WA 5 Division of Medical Oncology, University of Washington, Seattle, WA 6
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Great to see the work of our very talented trainees being presented at #ASH23! @emilyliangmd and Dr. Wuliji! 2143 Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy https://t.co/prkk9VXLXA… https://t.co/mdfCW9ZcKh https://t.co/4uaLmx7rGg
-
-
Mashup Score: 27Paper: Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting - 5 month(s) ago
Program: Oral and Poster Abstracts Session: 705. Cellular Immunotherapies: Late Phase and Co mmercially Available Therapies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, Clinical Research, Diseases, real-world evidence, Lymphoid Malignancies, Adverse Events Andrew J Portuguese, MD 1, Aya Albittar, MD 1 *, Emily C Liang, MD 1, Jennifer J. Huang, MD, PhD 1, Alexandre V Hirayama, MD 1 *, Erik L Kimble, MD 1, Lorenzo
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel - 5 month(s) ago
Disclosures. Hirayama:Novartis: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Nektar Therapeutics: Honoraria, Research Funding; Juno Therapeutic
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Welcome! You are invited to join a meeting: USC/CHLA Cell Therapy Seminar Series. After registering, you will receive a confirmation email about joining the meeting.
Source: usc.zoom.usCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Disclosures. Gauthier:Legend Biotech: Consultancy, Honoraria; Celgene (a Bristol Myers Squibb company): Research Funding; Century Therapeutics: Other: Independe
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis - 5 month(s) ago
OffLabel Disclosure:. Newell:Immunoscape: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees; Neogene
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Disclosures. Gauthier:Century Therapeutics: Other: Independent data review committee; Angiocrine Bioscience: Research Funding; Sobi: Consultancy, Honoraria, Res
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment - 5 month(s) ago
OffLabel Disclosure:. Landgren:Merck: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independ
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy - 5 month(s) ago
OffLabel Disclosure:. Banerjee:BMS: Consultancy; Janssen: Consultancy; Genentech: Consultancy; Sanofi: Consultancy; SparkCures: Consultancy; Caribou: Consultanc
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
#ASH23 Abstract 3495: Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy https://t.co/YTPXpmV5WI Presented by Dr. Jennifer Huang 6/18 https://t.co/3B79rphg5v